Research summary
Research HubSemax
Preclinical — 10 studies
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) fragments and studied for its effects on neurotrophic signaling and cognitive processes.
Being studied for
- Cognitive performance research
- Neurotrophic factor modulation
- Stress-response pathways
Published Research
Evidence profile
Predominantly preclinical
10 cited publications
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Additional indexed literature (10)
- Preclinical · Mechanistic studySemax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Liu R et al. · British journal of pharmacology · 2025 · PMID 40692165
- Preclinical · Mechanistic studySemax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing
Tomasello MF et al. · Bioinorganic chemistry and applications · 2025 · PMID 40496623
- Preclinical · Mechanistic studyThe Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease
Radchenko AI et al. · Acta naturae · 2025 · PMID 41479572
- Preclinical · Mechanistic studyThe Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons
Kolbaev SN et al. · Bulletin of experimental biology and medicine · 2025 · PMID 41171324
- Preclinical · Mechanistic studySemax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models
Sciacca MFM et al. · ACS chemical neuroscience · 2022 · PMID 35080861
- Preclinical · Mechanistic studySemax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
Glazova NY et al. · Neuropeptides · 2021 · PMID 33418449
- Preclinical · Mechanistic studyBrain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion
Sudarkina OY et al. · International journal of molecular sciences · 2021 · PMID 34201112
- Preclinical · Mechanistic study[The Peptide Drug ACTH(4-7)PGP (Semax) Suppresses mRNA Transcripts Encoding Proinflammatory Mediators Induced by Reversible Ischemia of the Rat Brain]
Dergunova LV et al. · Molekuliarnaia biologiia · 2021 · PMID 34097675
- Preclinical · Mechanistic studyNovel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats
Filippenkov IB et al. · Genes · 2020 · PMID 32580520
- Preclinical · Mechanistic studyComposition of Colon Microbiota in Rats Treated with ACTH(4-7)-PGP Peptide (Semax) under Conditions of Restraint Stress
Svishcheva MV et al. · Bulletin of experimental biology and medicine · 2020 · PMID 32737723
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.